000147217 001__ 147217
000147217 005__ 20240303003951.0
000147217 0247_ $$2doi$$a10.1002/jmri.26692
000147217 0247_ $$2pmid$$apmid:30793419
000147217 0247_ $$2ISSN$$a1053-1807
000147217 0247_ $$2ISSN$$a1522-2586
000147217 0247_ $$2altmetric$$aaltmetric:70354486
000147217 037__ $$aDKFZ-2019-02343
000147217 041__ $$aeng
000147217 082__ $$a610
000147217 1001_ $$0P:(DE-He78)a46ef05266eafb5f42c207880f97ebf6$$aSchwarz, Daniel$$b0$$eFirst author
000147217 245__ $$aSusceptibility-weighted imaging in malignant melanoma brain metastasis.
000147217 260__ $$aNew York, NY$$bWiley-Liss$$c2019
000147217 3367_ $$2DRIVER$$aarticle
000147217 3367_ $$2DataCite$$aOutput Types/Journal article
000147217 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681388167_19516
000147217 3367_ $$2BibTeX$$aARTICLE
000147217 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147217 3367_ $$00$$2EndNote$$aJournal Article
000147217 520__ $$aThe value of cerebral susceptibility-weighted imaging (SWI) in malignant melanoma (MM) patients remains controversial and the effect of melanin on SWI is not well understood.To systematically analyze the spectrum of intracerebral findings in MM brain metastases (BM) on SWI and to determine the diagnostic value of SWI.Retrospective.In all, 100 patients with melanoma BM (69 having received radiotherapy [RT] and 31 RT-naïve) and a control group of 100 melanoma patients without BM were included. For detailed analysis of signal characteristics, 175 metastases were studied.Gradient echo SWI sequence at 1.5, 3.0, and 9.4 T.Signal characteristics from melanotic and amelanotic BMs on SWI with a focus on blooming artifacts were analyzed, as well as the presence and longitudinal dynamics of isolated SWI blooming artifacts in patients with and without BM.Chi-squared and Student's t-test were used for contingency table measures and group data of signal and clinical characteristics, respectively.Melanotic and amelanotic metastases did not show significant differences of SWI blooming artifacts (38% vs. 43%, P = 0.61). Most metastases without an initial SWI artifact developed a signal dropout during follow-up (80%; 65/81). Isolated SWI artifacts were detected more frequently in patients with BM (20 vs. 9, P = 0.03), of which the majority were found in patients who had received RT (17 vs. 3, P = 0.08). None of these isolated SWI blooming artifacts turned into overt metastases over time (median follow-up: 8.5 months). Similar findings persisted as remnants of successfully treated metastases (88%; 7/8).We conclude that SWI provides little additional diagnostic benefit over standard T1 -weighted imaging, as melanin content alone does not cause diagnostically relevant SWI blooming. Signal transition of SWI may rather indicate secondary phenomena like microbleeding and/or metal scavenging. Our results suggest that isolated SWI artifacts do not constitute vital tumor tissue but represent unspecific microbleedings, RT-related parenchymal changes or posttherapeutic remnants of former metastatic lesions.3 Technical Efficacy Stage: 5 J. Magn. Reson. Imaging 2019;50:1251-1259.
000147217 536__ $$0G:(DE-HGF)POF3-314$$a314 - Tumor immunology (POF3-314)$$cPOF3-314$$fPOF III$$x0
000147217 588__ $$aDataset connected to CrossRef, PubMed,
000147217 7001_ $$aNiederle, Thomas$$b1
000147217 7001_ $$0P:(DE-HGF)0$$aMünch, Philipp$$b2
000147217 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b3$$udkfz
000147217 7001_ $$aHassel, Jessica C$$b4
000147217 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b5$$udkfz
000147217 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b6$$udkfz
000147217 7001_ $$0P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aWinkler, Frank$$b7$$udkfz
000147217 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b8$$udkfz
000147217 7001_ $$aHeiland, Sabine$$b9
000147217 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b10$$udkfz
000147217 7001_ $$aBendszus, Martin$$b11
000147217 7001_ $$0P:(DE-He78)4a14b13a372ab8bf853e4b650a6bd98a$$aBäumer, Philipp$$b12
000147217 7001_ $$0P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aBreckwoldt, Michael$$b13$$eLast author$$udkfz
000147217 773__ $$0PERI:(DE-600)1497154-9$$a10.1002/jmri.26692$$gVol. 50, no. 4, p. 1251 - 1259$$n4$$p1251 - 1259$$tJournal of magnetic resonance imaging$$v50$$x1522-2586$$y2019
000147217 909CO $$ooai:inrepo02.dkfz.de:147217$$pVDB
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46ef05266eafb5f42c207880f97ebf6$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000147217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000147217 9131_ $$0G:(DE-HGF)POF3-314$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTumor immunology$$x0
000147217 9141_ $$y2019
000147217 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000147217 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ MAGN RESON IMAGING : 2017
000147217 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147217 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147217 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147217 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147217 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147217 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147217 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147217 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147217 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147217 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000147217 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x1
000147217 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000147217 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x3
000147217 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x4
000147217 980__ $$ajournal
000147217 980__ $$aVDB
000147217 980__ $$aI:(DE-He78)E010-20160331
000147217 980__ $$aI:(DE-He78)D170-20160331
000147217 980__ $$aI:(DE-He78)C060-20160331
000147217 980__ $$aI:(DE-He78)B320-20160331
000147217 980__ $$aI:(DE-He78)L101-20160331
000147217 980__ $$aUNRESTRICTED